A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240
第一作者单位:[1]Peking Univ, Hosp 1, Dept Infect Dis, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Xu J. -H.,Jing C. -D.,Chen X. -F.,et al.A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240[J].JOURNAL OF HEPATOLOGY.2018,68:S517-S518.doi:10.1016/S0168-8278(18)31284-4.
APA:
Xu, J. -H.,Jing, C. -D.,Chen, X. -F.,Wang, S.,Zeng, Z....&Yu, Y. -Y..(2018).A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240.JOURNAL OF HEPATOLOGY,68,
MLA:
Xu, J. -H.,et al."A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of Chinese chronic hepatitis B predominantly genotype B or C: results at week 240".JOURNAL OF HEPATOLOGY 68.(2018):S517-S518